Two of Novo Nordisk's press releases, nine months apart, describe one and the same operator. The first ends their relationship over what it calls illegal mass compounding and deceptive marketing. The second names it as a launch partner for the cheapest Wegovy pricing Novo has ever offered.
That is the interesting thing about what a GLP-1 costs through Hers, and it is more useful than a price card, because the price card belongs to Novo Nordisk anyway.
First, what Hers actually is
Hers is a brand. Hims & Hers Health, Inc. runs both storefronts, files one set of accounts, and reports one subscriber count. There is no separate Hers company, no separate Hers balance sheet and no separate Hers pharmacy.
It gets its own page here for a reason that has nothing to do with corporate structure. Clickstream-corrected US search volume for "hers glp 1" is 10,200 a month, against 3,126 for "hims glp-1." The women's-health brand now out-searches the brand the company is named after, by roughly three to one, on this subject. When we first wrote about this operator we pooled the two and put everything on what Hims charges and what its filings say. The measurement says that was the wrong way round.
That page carries the subscriber economics — revenue per subscriber, the restructuring charges, where the growth is. This one carries the supply route and the record behind it, which is where the Hers-specific material turns out to be.
What the medicine costs
Hers routes prescriptions into the manufacturers' own channels, so the drug price is the manufacturer's. Novo Nordisk announced its subscription programme on 2026-03-31, and the prices are identical whichever telehealth company sells them:
| Product | 3-month | 6-month | 12-month | Standing self-pay |
|---|---|---|---|---|
| Wegovy pen (0.25–2.4 mg) | $329/mo | $299/mo | $249/mo | $349/mo |
| Wegovy pill (9 mg, 25 mg) | $289/mo | $269/mo | $249/mo | $299/mo |
Wegovy HD at 7.2 mg is to be added later. New patients have a separate two-fill introductory price of $199 for the 0.25 mg and 0.5 mg pen doses, which NovoCare's page on 2026-09-19 runs through 2026-12-31. The multi-month plans are prepaid, and the medicine-side arithmetic across the whole programme — including the point at which the pen and the pill converge on price — is worked through on what a GLP-1 costs through Ro, which is priced from the same Novo documents.
What Hers charges on top, we are not going to quote. Its storefront returns an automated-traffic block to our requests, this site does not work around those, and no current membership figure appears in any filing or release we could open. That number is the whole of what Hers adds to a manufacturer's price, so it is the one to get from Hers directly, in writing, before signing up.
The termination, in Novo's words
On 2025-06-23 Novo Nordisk published a release headed by the reason. Direct access to Wegovy through NovoCare Pharmacy would no longer be available to the company, and the release said why:
"Over one month into the collaboration, Hims & Hers Health, Inc. has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that put patient safety at risk."
The release went further, describing Novo's own investigation as finding that the "semaglutide" active ingredients in knock-off drugs sold by telehealth entities and compounding pharmacies were manufactured by foreign suppliers in China, and citing a Brookings report that FDA had never authorised those manufacturing processes.
Two months earlier, on 2025-04-29, Novo had named the company as one of three telehealth partners — with LifeMD and Ro — getting direct access to Wegovy through NovoCare Pharmacy at what was then $499 a month. The collaboration lasted under two months.
The return, also in Novo's words
On 2026-03-31 Novo announced the multi-month subscription programme, and listed who would be selling it:
"available beginning March 31, 2026, through Ro, WeightWatchers, LifeMD, with Hims & Hers, Sesame, and others to follow soon."
The same operator, named in the launch list for Novo's lowest-ever Wegovy prices, nine months after being publicly accused by the same manufacturer of illegal mass compounding.
Novo has published no explanation of the reversal that we could find, and we are not going to invent one. What can be said is what changed on the other side of the table in between, because the company disclosed it to the SEC — and the direction of travel is consistent with a manufacturer reconsidering.
What changed, from the company's own filing
From the Form 10-Q for the quarter ended 2026-06-30, filed 2026-08-10:
- It "evolved" its US weight-loss offering toward branded GLP-1 medications, with compounded ones available "on a limited scale."
- A majority of its United States revenue now comes from non-GLP-1 offerings.
- It previously sourced compounded GLP-1 products from 503B outsourcing facilities, permitted during the injectable semaglutide shortage; following the shortage's resolution, it states it "currently only use 503A compounding pharmacies."
That last line is the substantive one. A 503B outsourcing facility is registered with FDA and may compound in bulk without individual prescriptions; a 503A pharmacy compounds against a prescription for an identified patient. Moving from the first to the second is a move away from exactly the "mass sales" Novo's release named.
The company also launched a membership programme for its weight-loss offerings in March 2026 — the same month Novo's subscription programme launched, and the reason a Hers price and a Novo price are now two different numbers.
The rest of the record, stated fairly
A cost page that stopped at the price would be leaving out the thing most likely to affect whether this supply route exists in a year. Everything here is from the company's own filing, and none of it is a finding of wrongdoing.
The FDA statement, February 2026. FDA said it intends to restrict GLP-1 active pharmaceutical ingredients intended for non-FDA-approved compounded drugs "being mass-marketed as similar alternatives to FDA-approved drugs." The filing's own sentence: "We were directly named in the FDA Statement."
The DOJ referral, February 2026. Per the same filing, the General Counsel of HHS stated on X that HHS had referred the company to the Department of Justice "for investigation for potential violations of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions." Title 18 is the federal criminal code. The company adds: "At this time, it is unclear what actions the FDA, HHS, or DOJ may take."
The SEC investigation. The Division of Enforcement notified the company that it had opened an investigation and asked it to preserve documents concerning its public statements and disclosures about compounded semaglutide and related business relationships.
The securities and derivative suits. A securities class action covers statements made between 2025-04-29 and 2025-06-22 — the window between Novo's collaboration announcement and its termination — alleging misrepresentations about the relationship with Novo Nordisk. Three shareholder derivative actions in the Northern District of California relate to the same matters and are stayed. The company states it does not currently consider a loss on these lawsuits to be probable.
The patent suit is over, for now, and this is the fact most often reported stale. Novo Nordisk filed in the District of Delaware on 2026-02-09 over US Patent 8,129,343, seeking damages, enhanced damages for alleged willful infringement, and an injunction running until the patent expires on 2031-12-05. On 2026-03-09 Novo voluntarily dismissed all claims without prejudice and the court closed the case, reserving the right to refile. Both halves sit in the same paragraph of the 10-Q, which is presumably why so much coverage carries only the first.
Note the date. The dismissal came on 9 March; the subscription release naming the company came on 31 March. Whatever the reason for the reversal, it happened in that window.
What this means for a reader deciding
Three things follow from the record, and none of them is a verdict.
The medicine is the manufacturer's, so the drug price is not a reason to choose or avoid this route. $249 on a twelve-month Wegovy plan is $249 wherever it is bought.
The compounded route is the one carrying the risk, and the company has been moving off it — to branded products, to 503A pharmacies, to a majority of revenue from elsewhere. Someone buying an FDA-approved Wegovy pen through Hers is not buying the thing the regulators have been writing about.
The unresolved items are unresolved. A DOJ referral, an FDA restriction stated as an intention, and an SEC investigation are all live, and Novo's dismissal was expressly without prejudice. For anyone prepaying twelve months of anything, that is the relevant uncertainty, and it argues for knowing the cancellation terms before paying rather than for avoiding the route.
As our methodology puts it, a review with nothing critical in it has not been done properly — and the corollary holds too: the critical material here is a public record of allegations and investigations, not a conclusion, and we are not dressing it up as one.
Sources
All read 2026-09-19.
- Hims & Hers Health, Inc., Form 10-Q for the quarter ended 2026-06-30, filed 2026-08-10, SEC accession 0001773751-26-000163 — the FDA naming, the HHS/DOJ referral, the SEC investigation, the securities and derivative actions, the patent suit and its dismissal, the 503A/503B change, the revenue mix.
- Novo Nordisk, "Novo Nordisk terminates collaboration with Hims & Hers Health, Inc. due to concerns about their illegal mass compounding and deceptive marketing", 2025-06-23.
- Novo Nordisk, "Novo Nordisk launches first and only multi-month subscription program for FDA-approved Wegovy", 2026-03-31 — the price ladder and the launch-partner list.
- Novo Nordisk, "Novo Nordisk expands patient access to authentic, FDA-approved Wegovy via collaborations with multiple telehealth organizations", 2025-04-29 — the original three partners and the $499 price.
- NovoCare Pharmacy pricing page — standing self-pay prices and the introductory offer's current end date.